PT - JOURNAL ARTICLE AU - Silva Kasela AU - Victor E Ortega AU - Molly Martorella AU - Suresh Garudadri AU - Jenna Nguyen AU - Elizabeth Ampleford AU - Anu Pasanen AU - Srilaxmi Nerella AU - Kristina L Buschur AU - Igor Z Barjaktarevic AU - R Graham Barr AU - Eugene R Bleecker AU - Russell P Bowler AU - Alejandro P Comellas AU - Christopher B Cooper AU - David J Couper AU - Gerard J Criner AU - Jeffrey L Curtis AU - MeiLan K Han AU - Nadia N Hansel AU - Eric A Hoffman AU - Robert J Kaner AU - Jerry A Krishnan AU - Fernando J Martinez AU - Merry-Lynn N McDonald AU - Deborah A Meyers AU - Robert Paine, 3rd AU - Stephen P Peters AU - Mario Castro AU - Loren C Denlinger AU - Serpil C Erzurum AU - John V Fahy AU - Elliot Israel AU - Nizar N Jarjour AU - Bruce D Levy AU - Xingnan Li AU - Wendy C Moore AU - Sally E Wenzel AU - Joe Zein AU - NHLBI SubPopulations and InteRmediate Outcome Measures In COPD Study (SPIROMICS) AU - NHLBI Trans-Omics for Precision Medicine (TOPMed) Consortium AU - Charles Langelier AU - Prescott G Woodruff AU - Tuuli Lappalainen AU - Stephanie A Christenson TI - Genetic and non-genetic factors affecting the expression of COVID-19 relevant genes in the large airway epithelium AID - 10.1101/2020.10.01.20202820 DP - 2020 Jan 01 TA - medRxiv PG - 2020.10.01.20202820 4099 - http://medrxiv.org/content/early/2020/10/04/2020.10.01.20202820.short 4100 - http://medrxiv.org/content/early/2020/10/04/2020.10.01.20202820.full AB - Particular host and environmental factors influence susceptibility to severe COVID-19. We analyzed RNA-sequencing data from bronchial epithelial brushings - a relevant tissue for SARS-CoV-2 infection - obtained from three cohorts of uninfected individuals, and investigated how non-genetic and genetic factors affect the regulation of host genes implicated in COVID-19. We found that ACE2 expression was higher in relation to active smoking, obesity, and hypertension that are known risk factors of COVID-19 severity, while an association with interferon-related inflammation was driven by the truncated, non-binding ACE2 isoform. We discovered that expression patterns of a suppressed airway immune response to early SARS-CoV-2 infection, compared to other viruses, are similar to patterns associated with obesity, hypertension, and cardiovascular disease, which may thus contribute to a COVID-19-susceptible airway environment. eQTL mapping identified regulatory variants for genes implicated in COVID-19, some of which had pheWAS evidence for their potential role in respiratory infections. These data provide evidence that clinically relevant variation in the expression of COVID-19-related genes is associated with host factors, environmental exposures, and likely host genetic variation.Competing Interest StatementS.A.C. advises for AstraZeneca, GlaxoSmithKline, Glenmark Pharmaceuticals, and Amgen, gave invited lectures to Sonovion and Genentech, and writes for UpToDate. T.L. advises and has equity in Variant Bio, and is a member of the scientific advisory board of Goldfinch Bio. V.E.O. has served and currently serves on Independent Data and Monitoring Committee for Regeneron and Sanofi for COVID-19 therapeutic clinical trials unrelated to the current manuscript.Funding StatementThis work was funded by following funding sources: R01HL142992 (V.E.O.), R01HL137880 (V.E.O.), F30HG011194 (M.M.), R01MH106842 (T.L.), R01HL142028 (T.L., R.G.B. and S.K.), R01GM122924 (T.L.), UM1HG008901 (T.L.), R01GM124486 (T.L.), K23HL123778 (S.A.C.), R01HL121774 (S.A.C.), U01HL137880 (S.A.C.). Molecular data for the Trans-Omics in Precision Medicine (TOPMed) program was supported by the National Heart, Lung and Blood Institute (NHLBI). Genome Sequencing for "NHLBI TOPMed: SubPopulations and InteRmediate Outcome Measures In COPD Study" (phs001927) was performed at the Broad Institute Genomics Platform (HHSN268201600034I). Core support including centralized genomic read mapping and genotype calling, along with variant quality metrics and filtering were provided by the TOPMed Informatics Research Center (3R01HL-117626-02S1; contract HHSN268201800002I). Core support including phenotype harmonization, data management, sample-identity QC, and general program coordination were provided by the TOPMed Data Coordinating Center (R01HL-120393; U01HL-120393; contract HHSN268201800001I). SPIROMICS was supported by contracts from the NIH/NHLBI (HHSN268200900013C, HHSN268200900014C, HHSN268200900015C, HHSN268200900016C, HHSN268200900017C, HHSN268200900018C, HHSN268200900019C, HHSN268200900020C), grants from the NIH/NHLBI (U01 HL137880 and U24 HL141762), and supplemented by contributions made through the Foundation for the NIH and the COPD Foundation from AstraZeneca/MedImmune; Bayer; Bellerophon Therapeutics; Boehringer-Ingelheim Pharmaceuticals, Inc.; Chiesi Farmaceutici S.p.A.; Forest Research Institute, Inc.; GlaxoSmithKline; Grifols Therapeutics, Inc.; Ikaria, Inc.; Novartis Pharmaceuticals Corporation; Nycomed GmbH; ProterixBio; Regeneron Pharmaceuticals, Inc.; Sanofi; Sunovion; Takeda Pharmaceutical Company; and Theravance Biopharma and Mylan.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Columbia University IRB 2 (AAAE9315), University of Iowa IRB-01 (201308719), Johns Hopkins IRB-5 (NA_00035701), UCLA Medical IRB 1 (MIRB1) (10001740/ 18-000403), University of Michigan IRBMED B1 Board (HUM00036346/ HUM00141222), National Jewish Health IRB (HS2678), UCSF IRB Parnassus Panel (10-03169), Temple University IRB A2 (21416), U of Alabama at Birmingham IRB #2 (120906004), University of Illinois IRB #3 (2013-0939), University of Utah IRB Panel Review Board 5 (00027298/ 00108836), Wake Forest University IRB #5 (00012805/ 00048727), UNC Non-Biomedical IRB (10-0048), UCLA Medical IRB 1 (MIRB1) (18-000458), University of Iowa IRB-01 (201003733).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe SPIROMICS gene expression data will be available in dbGaP. The SARP gene expression data will be available through the Gene Expression Omnibus (GEO). The MAST dataset is available in GEO under accession number GSE67472. TOPMed WGS freeze 9 data are available in dbGaP under accession number phs001927. Full eQTL summary statistics for the 496 COVID-19-related genes can be downloaded from https://github.com/LappalainenLab/spiromics-covid19-eqtl/tree/master/eqtl/summary_stats. https://github.com/LappalainenLab/spiromics-covid19-eqtl/tree/master/eqtl/summary_stats